UroGen Pharma Ltd. (URGN) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $12.45M | +40.2% |
| 2024 | $8.88M | -5.1% |
| 2023 | $9.36M | +22.3% |
| 2022 | $7.65M | +48.4% |
| 2021 | $5.16M | +411.1% |
| 2020 | $1.01M | — |
| 2018 | $1.80M | +200.5% |
| 2017 | $600.0K | +2042.9% |
| 2016 | $28.0K | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $12.45M | +40.2% |
| 2024 | $8.88M | -5.1% |
| 2023 | $9.36M | +22.3% |
| 2022 | $7.65M | +48.4% |
| 2021 | $5.16M | +411.1% |
| 2020 | $1.01M | — |
| 2018 | $1.80M | +200.5% |
| 2017 | $600.0K | +2042.9% |
| 2016 | $28.0K | — |